Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
XTLB — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

1.57

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

2.88

Target Price

6

Analyst Recom

1

Performance Q

10.11

Upside

N/A

Beta

1.4

Ticker: XTLB



19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13XTLB2.895N/AN/A0
2026-07-14XTLB2.9N/AN/A0
2026-07-15XTLB2.95N/AN/A0
2026-07-16XTLB2.86N/AN/A0
2026-07-17XTLB2.85N/AN/A0
2026-07-20XTLB2.86N/AN/A0
2026-07-21XTLB2.86N/AN/A0
2026-07-22XTLB2.92N/AN/A0
2026-07-23XTLB2.78N/AN/A0
2026-07-24XTLB2.86N/AN/A0
2026-07-27XTLB2.87N/AN/A0
2026-07-28XTLB2.79N/AN/A0
2026-07-29XTLB2.96N/AN/A0
2026-07-30XTLB2.81N/AN/A0
2026-07-31XTLB2.82N/AN/A0
2026-08-03XTLB2.77N/AN/A0
2026-08-04XTLB2.8799N/AN/A0
2026-08-05XTLB2.87N/AN/A0
2026-08-07XTLB2.8N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13XTLB2.81- - -
2026-07-14XTLB2.91- - -
2026-07-15XTLB2.92- - -
2026-07-16XTLB2.89- - -
2026-07-17XTLB2.88- - -
2026-07-20XTLB2.76- - -
2026-07-21XTLB2.95- - -
2026-07-22XTLB2.92- - -
2026-07-23XTLB2.92- - -
2026-07-24XTLB2.81- - -
2026-07-27XTLB2.87- - -
2026-07-28XTLB2.93- - -
2026-07-29XTLB2.80- - -
2026-07-30XTLB2.81- - -
2026-07-31XTLB2.75- - -
2026-08-03XTLB2.80- - -
2026-08-04XTLB2.80- - -
2026-08-05XTLB2.88- - -
2026-08-06XTLB2.80- - -
2026-08-07XTLB2.88- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13XTLB0.00-97.670.41
2026-07-14XTLB0.00-97.670.41
2026-07-15XTLB0.00-97.670.41
2026-07-16XTLB0.00-97.670.41
2026-07-17XTLB0.00-97.670.41
2026-07-20XTLB0.00-97.660.41
2026-07-21XTLB0.00-97.660.41
2026-07-22XTLB0.00-97.660.41
2026-07-23XTLB0.00-97.660.41
2026-07-24XTLB0.00-97.660.41
2026-07-27XTLB0.00-97.381.57
2026-07-28XTLB0.00-97.381.57
2026-07-29XTLB0.00-97.381.57
2026-07-30XTLB0.00-97.381.57
2026-07-31XTLB0.00-97.381.57
2026-08-03XTLB0.00-95.971.57
2026-08-04XTLB0.00-95.971.57
2026-08-05XTLB0.00-95.971.57
2026-08-06XTLB0.00-95.971.57
2026-08-07XTLB0.00-95.971.57
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-95.97

Beta

1.4

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

2

Growth Score

Sentiment Score

37

Actual DrawDown %

87.3

Max Drawdown 5-Year %

-90.1

Target Price

6

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.02

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ XTLB Healthcare
$2.94
📉
Swing / Pullback
Buy the dip on strong trends
39 /100
WEAK
Trend
8/20
Pullback
6/25
Volume
11/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
56.2
Range 1M
60%
Sup Dist
6.8%
🚀
Momentum Growth
Ride accelerating trends
N/A
14 /100
WEAK
Momentum
4/25
Growth
8/30
Estimates
0/20
Inst/Vol
2/15
Options
0/10
EPS Yr
0%
EPS NY
0%
52W%
9.6%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +104.1% upside
Quality
2/30
Valuation
16/30
Growth
3/25
Stability
4/10
LT Trend
4/5
Upside
+104.1%
Quality
2
Click a card to see score breakdown Full Analysis →
XTLB — P/E HistoricalBiotechnology
XTL Biopharmaceuticals Ltd.
Sector: Healthcare
Industry: Biotechnology
Employees: 4
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
XTLB

Latest News

—
Caricamento notizie per XTLB…
stock quote shares XTLB – X.T.L. Biopharmaceuticals Ltd. ADR Stock Price stock today
news today XTLB – X.T.L. Biopharmaceuticals Ltd. ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch XTLB – X.T.L. Biopharmaceuticals Ltd. ADR yahoo finance google finance
stock history XTLB – X.T.L. Biopharmaceuticals Ltd. ADR invest stock market
stock prices XTLB premarket after hours
ticker XTLB fair value insiders trading